HIK.L
Hikma Pharmaceuticals
Health Care · Pharmaceuticals · LSE
$1,417.50
Close 2026-05-09
✓ ETHICAL PASS

UNKNOWN MOAT
HIGH
Data Confidence: 100%
Full financial profile available
Market Cap
$3.0B
Trailing P/E
10.58
Forward P/E
7.73
Rev Growth
+8.5%
Profit Margin
12.0%
ROE
16.5%
Analyst Target
$1,895.56
Recommendation
BUY
Ethical Screen
Business ActivityPASS
Debt Ratio (0.28%)PASS
Cash Ratio (0.04%)PASS
Receivables Ratio (0.18%)PASS
Revenue Ratio (0.03%)PASS
OverallPASS
Score Ethical: 76.6
Score Valuation: 72.5
Score Quality: 49.0
Score Combined: 56.2
Fair Value Est: $516.78 · Margin of Safety: -174.3% · Tier: AVOID

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation100.0
Quality48.7
Cash Flow0.0
Moat40.0
Balance Sheet0.0
Debt Purity14.3
Liquid Purity88.4
Rev Purity45.6
Compliance45.3
Tier: WATCH · Score: 28.5 · Rank: #5003
Earnings History (Last 8 Quarters)
DateEPS Est.Reported EPSSurprise %
2026-08-06Pending--
Insider Transactions
DateNameRoleSharesValue
2026-05-08Hikma Pharmaceuticals PLC118,300$2.3M
2026-05-07Hikma Pharmaceuticals PLC116,988$2.2M
2026-05-06Hikma Pharmaceuticals PLC62,430$1.2M
2026-05-05Hikma Pharmaceuticals PLC90,471$1.7M
2026-05-05Hill (Julie)178$3.4K
2026-05-05Ringdal (Susan)2,337$44.6K
2026-05-05Arkhagha (Hussein)407$7.8K
2026-05-01Hikma Pharmaceuticals PLC94,669$1.8M
2026-04-30Hikma Pharmaceuticals PLC101,001$1.9M
2026-04-29Hikma Pharmaceuticals PLC88,131$1.7M
Top Institutional Holders
HolderSharesValue% Held
Paradigm Asset Management Company, LLC955.0$1.4M
Analyst Recommendations
3 Months Ago
3
7
11 analysts
2 Months Ago
3
7
11 analysts
Last Month
3
6
10 analysts
Current
3
7
11 analysts
Strong Buy Buy Hold Sell Strong Sell
Additional Fundamentals
Enterprise Value
$4.6B
Price/Book
1.66
Beta
0.643
Analysts
11
Total Revenue (TTM)
$3.3B
Total Debt
$1.6B
Earnings Growth
+23.5%
Dividend Yield
4.3%
Rec. Mean
1.55

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 56.2 (P88 — top 12.1% of scored tickers). Unknown Moat. Ethical PASS. 11 analysts at Buy.
Price: $1,417.50 | Target: $1,895.56 (+34%) | Fair Value: $516.78 (+-64%)
Score
56
Moat
Unknown
Conviction
Standard
Upside
+34%
The Fundamentals
Revenue Growth+8.5%
Profit Margin0.0%
ROE16.5%
Forward P/E7.7
Market Cap$3.0B
Earnings Track Record
DateEstimateReportedSurprise
2026-08-06$—Pending
Position Sizing Scenarios
Stop: $1,204.88 (-15%) | Entry: $1,417.50
SharesCostProfit to TargetR:R
To Consensus ($1,895.56, 11 analysts)
10$14,175.00+$4,780.60 (34%)2.2R
50$70,875.00+$23,903.00 (34%)2.2R
100$141,750.00+$47,806.00 (34%)2.2R
To Fair Value ($516.78)
10$14,175.00+$-9,007.20 (-64%)-4.2R
50$70,875.00+$-45,036.00 (-64%)-4.2R
100$141,750.00+$-90,072.00 (-64%)-4.2R
Risk Factors
  • No elevated risk flags in current data
The Verdict
Hikma Pharmaceuticals passes all ethical screens and holds a unknown competitive moat.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

C
Quant Score
48.7
Risk Grade
LOW_RISK
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-2.0%
worst expected daily loss, 19 in 20 days
CVaR 95%
-4.4%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
-0.46
above 1.0 is good
Max Drawdown
-49.1%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
72
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
BELOW_200
Bollinger Position
NEAR_UPPER
Beta
Relative Volume
0.8x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
WD0.313
MUT.L0.308
BBSI0.303
MRCH.L0.301
EDIN.L0.300
Inverse Correlated
TickerCorrelation
EFXT-0.218
SUNC-0.193
PLBL-0.155
FA-0.148
APA-0.147
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Wednesday
Worst Day
Thursday
Best Month
May
Worst Month
Feb
Fri-Mon Effect
-0.03356511984938762
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+5.5%
3M Return
-9.3%
6M Return
-5.3%
12M Return
-29.9%
Momentum Rank
#3336
Momentum Signal
FLAT

Get our daily market read free. Join thousands of traders.

Free Explorer Access